Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibition: A Lipocrinologic Review.
This review describes the endocrine impact of proprotein convertase subtilisin kexin 9 (PCSK9) biology and PCSK9 inhibition. It discusses the relationship of the pituitary, thyroid, parathyroid, pancreatic, adrenal and gonadal hormones with lipid health. It also explores the status of PCSK9, and impact of PCSK9 inhibition, in dyslipidemia associated with endocrinopathy. This review should stimulate interest in the lipocrinologic aspects of PCSK9 inhibitors.